Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock

Key Points

• CEO Nello Mainolfi sold 30,000 shares on Feb. 25 at an average price of $90.26 for proceeds of $2,707,800, leaving him with 666,195 shares (a 4.31% ownership reduction).
• The Feb. 25 sale continues recent insider selling by Mainolfi (30,000 shares on Dec. 31 at $78.06 and 100,000 shares on Dec. 8 at $89.17), indicating sustained executive stock exits.
• Despite the insider sales, analysts remain largely bullish with an average "Buy" rating and a consensus target near $117, while KYMR trades around $90.68 with a ~$6.52 billion market cap.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the sale, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, December 31st, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $78.06, for a total transaction of $2,341,800.00.
• On Monday, December 8th, Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.17, for a total transaction of $8,917,000.00.

Kymera Therapeutics Stock Down 0.4%

Shares of KYMR stock traded down $0.33 during trading hours on Wednesday, reaching $90.68. 1,052,404 shares of the stock traded hands, compared to its average volume of 771,072. The firm has a market capitalization of $6.52 billion, a PE ratio of -25.26 and a beta of 2.21. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The business has a fifty day moving average price of $77.89 and a 200 day moving average price of $64.50.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KYMR. PNC Financial Services Group Inc. boosted its stake in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after purchasing an additional 770 shares during the period. Smartleaf Asset Management LLC grew its position in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after acquiring an additional 1,083 shares during the period. Finally, Bessemer Group Inc. raised its holdings in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after acquiring an additional 815 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KYMR. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, December 11th. Piper Sandler reiterated an "overweight" rating and issued a $125.00 target price (up from $98.00) on shares of Kymera Therapeutics in a report on Tuesday, December 9th. B. Riley Financial raised their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. UBS Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Thursday, December 4th. Finally, Oppenheimer increased their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of "Buy" and an average target price of $117.00.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.